Neurogene (NGNE) analyst forecast and price target
Analyst forecast
Consensus of 10 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $65.00 from $70.00 | Aug 12, 2026 |
| Guggenheim | Maintained | Buy | $81.00 from $69.00 | Aug 12, 2026 |
| Canaccord Genuity | Maintained | Buy | $166.00 from $180.00 | Aug 12, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $70.00 | Jun 9, 2026 |
| Canaccord Genuity | Maintained | Buy | $180.00 from $200.00 | Apr 6, 2026 |
| Canaccord Genuity | Initiated Coverage | Buy | $200.00 | Feb 27, 2026 |
| LifeSci Capital | Initiated Coverage | Outperform | $50.00 | Jan 26, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $70.00 | Jan 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $70.00 from $65.00 | Nov 13, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $65.00 from $45.00 | Oct 31, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 | Oct 9, 2025 |
| Craig-Hallum | Initiated Coverage | Buy | $50.00 | Jun 17, 2025 |
| BMO Capital | Maintained | Outperform | $26.00 from $22.00 | Jun 12, 2025 |
| BMO Capital | Maintained | Outperform | $22.00 from $16.00 | May 20, 2025 |
| Baird | Downgraded | Outperform → Neutral | $24.00 from $38.00 | May 16, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 from $50.00 | May 13, 2025 |
| BMO Capital | Maintained | Outperform | $16.00 from $45.00 | Apr 14, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $50.00 from $55.00 | Mar 25, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $55.00 | Nov 25, 2024 |
| BMO Capital | Maintained | Outperform | $45.00 from $60.00 | Nov 20, 2024 |
Frequently asked questions
What is the price target for NGNE stock?
The average 12-month analyst price target for Neurogene (NGNE) is $104.00, with a high estimate of $166.00 and a low of $65.00, across 3 analysts.
Is NGNE a buy, sell, or hold?
Analysts covering Neurogene currently average a Buy rating: 10 buy, 0 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for NGNE?
The average price target of $104.00 implies 188.65% upside from the last price of $36.03.
What is the latest analyst rating on NGNE?
On Aug 12, 2026, HC Wainwright & Co. maintained Neurogene at Buy with a price target of $65.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.